Efbemalenograstim Alfa
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Efbemalenograstim Alfa, covering 2025-09-23 to 2025-09-23. Get the full timeline:
Most recent: Clinical Trial Update: Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN [Phase 2]